Development of a prognostic prediction model based on microRNA-1269a in esophageal cancer

Table 1 Clinical characteristics of esophageal cancer patients in this study, n (%)

Characteristics	Normal group, n = 52	ESCA group, n = 125	P value
Age in yr	58.7 ± 4.8	60 ± 5.4	0.857
Gender			0.962
Female	21 (40.4)	50 (53.6)
Male	31 (59.6)	75 (46.4)
Smoking history			0.383
Yes	32 (61.5)	68 (54.4)
No	20 (38.5)	57 (45.6)
Alcohol consumption			0.567
Yes	18 (34.6)	49 (39.2)
No	34 (65.4)	76 (60.8)
Location
Upper area		16 (12.8)
Middle area		41 (32.8)
Lower area		68 (54.4)
Histologic grade
G 1		38 (30.4)
G 2 + G 3		87 (69.6)
AJCC stage
Stage I + II		74 (59.2)
Stage III + IV		51 (40.8)
Tumor stage
T1 + T2		52 (41.6)
T3 + T4		73 (58.4)
Lymph stage
N0		59 (48.8)
N1 + N2 + N3		66 (51.2)
Metastatic stage
M0		119 (95.2)
M1		6 (4.8)

AJCC: American Joint Committee on Cancer; ESCA: Esophageal cancer; G 1: Grade 1, high differentiation; G 2: Grade 2, moderate differentiation; G 3: Grade 3, low differentiation.

Table 2 Relationship between microRNA-1269a and pathological data

Characteristics	High expression, n = 62	Low expression, n = 63	P value
Age in yr			0.531
< 60	33 (53.2)	30 (47.6)
≥ 60	29 (46.7)	33 (52.3)
Gender			0.77
Female	24 (38.7)	26 (41.3)
Male	38 (61.2)	37 (58.7)
Location			0.8
Upper + middle area	24 (38.7)	23 (36.5)
Lower area	38 (61.2)	40 (63.5)
Histologic grade			0.003
G 1	27 (38.7)	12 (38.7)
G 2 + G 3	35 (38.7)	51 (38.7)
AJCC stage			0.001
Stage I + II	21 (33.9)	53 (84.1)
Stage III + IV	41 (66.1)	10 (15.9)
Tumor stage			0.004
T1 + T2	18 (29.0)	34 (54.0)
T3 + T4	44 (70.0)	29 (46.0)
Lymph stage			0.009
N0	22 (35.5)	37 (58.7)
N1 + N2 + N3	40 (64.5)	26 (41.3)
Metastatic stage			0.011
M0	56 (0.0)	63 (100.0)
M1	6 (100.0)	0 (0.0)

AJCC: American Joint Committee on Cancer; ESCA: Esophageal cancer; G 1: Grade 1, high differentiation; G 2: Grade 2, moderate differentiation; G 3: Grade 3, low differentiation.

Table 3 Gene Ontology enrichment analysis of microRNA-1269a target genes

ID	Term	Gene	Count	P value
GO:0005515	Protein binding	CLTC, WDR6, PUM2, MATR3, AKAP11, SMARCA4, UBN1, YWHAZ, BSDC1, SMG1, ZNF146, BACH2, KHSRP, TPM3, TAGLN2, PTBP1, PHKG2, TNPO2, MAP1A, ZBTB4, HMGCR, AP3D1, FN1, PTMA, TBP, CCND2, NCL, CDK6, SEC61A1	29	3.58E-11
GO:0005829	Cytosol	YWHAZ, MAP1A, CCND2, SMG1, WDR1, PTMA, ZBTB4, BACH2, KHSRP, TPM3, CLTC, SEC61A1, PUM2, WDR6, CDK6, AKAP11, TAGLN2, PHKG2, ZNF146	19	3.79E-09
GO:0005634	Nucleus	YWHAZ, ZNF146, CCND2, SMG1, MATR3, PTMA, ZBTB4, BACH2, SLC25A1, KHSRP, NCL, CDK6, TBP, PTBP1, SMARCA4, UBN1, TNPO2	17	3.02E-07
GO:0005654	Nucleoplasm	YWHAZ, CCND2, SMG1, PTMA, ZBTB4, BACH2, KHSRP, NCL, CDK6, TBP, PTBP1, SMARCA4, UBN1	13	5.25E-06
GO:0005737	Cytoplasm	YWHAZ, MAP1A, CCND2, SMG1, WDR6, TBP, KHSRP, PUM2, CDK6, AKAP11, TNPO2	11	0.0013
GO:0070062	Extracellular exosome	YWHAZ, FN1, WDR1, SLC25A1, KHSRP, TPM3, NCL, CLTC, PGAM1, PTBP1, TAGLN2	11	8.89E-07
GO:0003723	RNA binding	YWHAZ, WDR6, SMG1, CLTC, KHSRP, PUM2, NCL, MATR3, PTBP1, SMARCA4	10	1.64E-07
GO:0016020	Membrane	CLTC, KHSRP, SEC61A1, NCL, MATR3, PTBP1, SMARCA4, AP3D1	8	0.00032
GO:0042802	Identical protein binding	YWHAZ, HMGCR, FN1, KHSRP, NCL, MATR3	6	0.00144
GO:0005730	Nucleolus	ZNF146, KHSRP, SMARCA4, UBN1, ZBTB4	5	7.83E-05
GO:0003677	DNA binding	ZNF146, CCND2, NCL, AKAP11, PTBP1, SMARCA4	6	0.00369
GO:0000122	Negative regulation of transcription by RNA polymerase II	BACH2, SMARCA4, CDK6, ZBTB4	4	0.00569
GO:0019901	Protein kinase binding	YWHAZ, CCND2, CLTC, ZBTB4	4	0.00067
GO:0003729	mRNA binding	PUM2, PTBP1, KHSRP, MATR3	4	2.90E-05
GO:0032991	Protein-containing complex	TBP, SMARCA4, CLTC	3	0.01671
GO:0043066	Negative regulation of apoptotic process	YWHAZ, CCND2, PTMA	3	0.00866
GO:0006468	Protein phosphorylation	YWHAZ, PHKG2, CDK6	3	0.00703
GO:0098978	Glutamatergic synapse	YWHAZ, AP3D1, NPTX1	3	0.00361
GO:0019899	Enzyme binding	TBP, PHKG2, FN1	3	0.00358
GO:0051301	Cell division	CCND2, CLTC, CDK6	3	0.00339
GO:0008134	Transcription factor binding	YWHAZ, TBP, SMARCA4	3	0.00285
GO:0001525	Angiogenesis	YWHAZ, NCL, FN1	3	0.00118
GO:0030054	Cell junction	KHSRP, SLC7A2, WDR1	3	0.00062
GO:0005198	Structural molecule activity	MAP1A, CLTC, MATR3	3	0.00043
GO:0043488	Regulation of mRNA stability	YWHAZ, PUM2, KHSRP	3	0.00013

Table 4 Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of microRNA-1269a target genes

ID	Term	Gene	Count	P value
hsa04151	PI3K-Akt signaling pathway	YWHAZ, CCND2, FN1, CDK6, IGF1, MET, PRLR, MAGI2, CREB5	9	0.00863
hsa05200	Pathways in cancer	CCND2, TPM3, FN1, CDK6, IGF2, NOTCH3, MET, CDK6	8	0.02116
hsa04110	Cell cycle	YWHAZ, CCND2, CDK6, E2F5, YWHAQ, CCND1, STAG2	7	0.00751
hsa04115	p53 signaling pathway	CCND2, CDK6, CCND1, WIG1, CDK6, IGF1	6	0.03033
hsa04510	Focal adhesion	CCND2, FN1, ITGB3, IGF1, MET	5	0.02116
hsa05203	Viral carcinogenesis	YWHAZ, TBP, CCND2, CDK6	4	0.00190
hsa05165	Human papillomavirus infection	TBP, CCND2, FN1, CDK6	4	0.00751
hsa05100	Bacterial invasion of epithelial cells	CLTC, FN1	2	0.03033
hsa05222	Small cell lung cancer	FN1, CDK6	2	0.03757
hsa04922	Glucagon signaling pathway	PHKG2, PGAM1	2	0.03757
hsa04142	Lysosome	AP3D1, CLTC	2	0.03757
hsa04390	Hippo signaling pathway	YWHAZ, CCND2	2	0.03757
hsa04218	Cellular senescence	CCND2, CDK6	2	0.03757
hsa05130	Pathogenic Escherichia coli infection	YWHAZ, NCL	2	0.04294